Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OSTX Stock Forecast 2026-2027
$1.78
Current Price
$82.40M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to OSTX Price Targets
+630.3%
To High Target of $13.00
+422.2%
To Median Target of $9.30
+237.1%
To Low Target of $6.00
OSTX Price Momentum
-16.8%
1 Week Change
+2.9%
1 Month Change
+6.6%
1 Year Change
+27.1%
Year-to-Date Change
-30.7%
From 52W High of $2.57
+54.8%
From 52W Low of $1.15
📊 TOP ANALYST CALLS
Did OSTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if OS Therapies is one of their latest high-conviction picks.
Latest OSTX Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, OSTX has a bullish consensus with a median price target of $9.30 (ranging from $6.00 to $13.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $1.78, the median forecast implies a 422.2% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OSTX Analyst Ratings
3
Buy
0
Hold
0
Sell
OSTX Price Target Range
Low
$6.00
Average
$9.30
High
$13.00
Current: $1.78
Latest OSTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OSTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2026 | Lake Street | Buy | Maintains | $N/A | |
| Apr 30, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Apr 8, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 27, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 9, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Feb 5, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 5, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 15, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 9, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 5, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 21, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 18, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Nov 17, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Oct 10, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 30, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 12, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 2, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 27, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 20, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 7, 2025 | D. Boral Capital | Buy | Maintains | $N/A |
Os Therapies Inc. (OSTX) Competitors
The following stocks are similar to OS Therapies based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
OSTX
OS Therapies
mkt cap
95.31M
Os Therapies Inc. (OSTX) Financial Data
Valuation Metrics
Market Cap
$82.40M
Enterprise Value
$81.66M
P/E Ratio
N/A
PEG Ratio
-17.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+1.2%
Current Ratio
0.1x
Debt/Equity
-0.1x
ROE
+471.7%
ROA
-366.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Os Therapies Inc. (OSTX) Business Model
About Os Therapies Inc.
What They Do
Develops innovative cancer treatments and therapies.
Business Model
The company generates revenue through the research, development, and commercialization of immunotherapy products aimed at improving cancer treatment outcomes. By conducting clinical trials and partnering with healthcare providers, it seeks to bring new therapies to market, thereby monetizing its innovative solutions.
Additional Information
Os Therapies Inc. is positioned within the biotechnology and pharmaceutical industries, focusing on personalized medicine. Their research efforts not only aim to enhance patient quality of life but also contribute to the scientific community's understanding of cancer, highlighting the company's commitment to addressing significant healthcare challenges.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4
CEO
Mr. Paul A. Romness M.P.H.
Country
United States
IPO Year
2024
Website
ostherapies.comOs Therapies Inc. (OSTX) Latest News & Analysis
Latest News
Quick Summary
OS Therapies (NYSE:OSTX) shares rose in premarket trading after the company reported statistically significant overall survival results from its Phase 2b trial of OST-HER2 at the 2.5-year mark.
Why It Matters
OS Therapies' significant Phase 2b trial results could boost investor confidence, potentially driving share prices higher due to improved prospects for product approval and market potential.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
OST-HER2 shows a 75% overall survival rate at 2.5 years, significantly higher than the 47% historical control (p = 0.003), with no new deaths since the 2-year data.
Why It Matters
The significant survival rate improvement for OST-HER2 indicates strong potential for the therapy, likely boosting investor confidence and interest in the company's future prospects.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
OS Therapies, Inc. (OSTX) will present 2.5-year survival data from its Phase 2b trial on OST-HER2 at the 2026 ASCO Annual Meeting, along with four related publications.
Why It Matters
The upcoming survival data release and related publications could significantly impact OS Therapies' stock price and investor sentiment, reflecting advancements in cancer treatment and potential market positioning.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
OS Therapies, Inc. (NYSE: OSTX) will present 2.5-year survival data at ASCO 2026 and participate in several conferences focused on partnerships and data presentations through June 2026.
Why It Matters
OS Therapies' participation in major conferences highlights its commitment to advancing cancer treatment, potentially boosting investor confidence in its innovative therapies and market position.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
OS Therapies closed $5.5M in financing and raised $5.7M in Q1 2026, extending cash runway into 2027. Key regulatory meetings are set for OST-HER2, targeting metastatic osteosarcoma.
Why It Matters
The financing and upcoming clinical milestones indicate strong cash support and potential approval pathways for OST-HER2, which could drive stock value and investor interest in OS Therapies.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
OS Therapies, Inc. (NYSE American: OSTX) will release its Q1 2026 financial results and business update on May 18, 2026. The company specializes in gene-edited cancer immunotherapies.
Why It Matters
OS Therapies' upcoming financial update could reveal key insights into its performance and prospects, impacting stock valuation and investor sentiment in the oncology sector.
Source: Newsfile Corp
Market Sentiment:
Neutral
Frequently Asked Questions About OSTX Stock
What is Os Therapies Inc.'s (OSTX) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Os Therapies Inc. (OSTX) has a median price target of $9.30. The highest price target is $13.00 and the lowest is $6.00.
Is OSTX stock a good investment in 2026?
According to current analyst ratings, OSTX has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.78. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OSTX stock?
Wall Street analysts predict OSTX stock could reach $9.30 in the next 12 months. This represents a 422.2% increase from the current price of $1.78. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Os Therapies Inc.'s business model?
The company generates revenue through the research, development, and commercialization of immunotherapy products aimed at improving cancer treatment outcomes. By conducting clinical trials and partnering with healthcare providers, it seeks to bring new therapies to market, thereby monetizing its innovative solutions.
What is the highest forecasted price for OSTX Os Therapies Inc.?
The highest price target for OSTX is $13.00 from at , which represents a 630.3% increase from the current price of $1.78.
What is the lowest forecasted price for OSTX Os Therapies Inc.?
The lowest price target for OSTX is $6.00 from at , which represents a 237.1% increase from the current price of $1.78.
What is the overall OSTX consensus from analysts for Os Therapies Inc.?
The overall analyst consensus for OSTX is bullish. Out of 1 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.30.
How accurate are OSTX stock price projections?
Stock price projections, including those for Os Therapies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 3:20 AM UTC